Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Issue of shares pursuant to the Long Term Incentive Plan

13th Aug 2018 12:39

Syncona Limited - Issue of shares pursuant to the Long Term Incentive Plan

Syncona Limited - Issue of shares pursuant to the Long Term Incentive Plan

PR Newswire

London, August 13

Syncona Limited

Issue of shares pursuant to the Long Term Incentive Plan

13 August 2018

Syncona Limited (the "Company") today announces that a total of 20,836 new ordinary shares will be issued in satisfaction of realisations under the Company’s Long Term Incentive Plan. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. 

In accordance with the rules of the Long Term Incentive Plan, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.

Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 16 August 2018.

[ENDS]

Enquiries

Syncona LtdAnnabel ClayTel: +44 (0) 20 7611 2031Northern Trust International Fund Administration Services (Guernsey) LimitedCompany SecretaryTel: 01481 745001

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.


Related Shares:

Syncona
FTSE 100 Latest
Value8,474.74
Change-133.74